Drugs / dacetuzumab
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT00664898 | May 2008 → Apr 2010 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00655837 | Apr 2008 → Feb 2010 | diffuse large B-cell lymphoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00556699 | Dec 2007 → Nov 2010 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00525447 | Aug 2007 → Jan 2010 | plasma cell myeloma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00103779 | Dec 2004 → Mar 2007 | non-Hodgkin lymphoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00079716 | Mar 2004 → Aug 2007 | plasma cell myeloma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00283101 | Jul 2005 → Oct 2006 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00529503 | Sep 2007 → Dec 2009 | diffuse large B-cell lymphoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00435916 | Dec 2006 → Jan 2009 | diffuse large B-cell lymphoma | Seagen Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dacetuzumab | “Dacetuzumab (SGN-40), a non-blocking, partial agonist, humanized IgG1, anti-CD40 monoclonal antibody, has previously demonstrated anti-lymphoma activity in a phase I study.” PMID 24919462 ↗ Jun 2014 |
| Known as | HU-S2C6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743005 ↗ |
| Known as | SGN-40 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00283101 ↗ |
| Action | Deplete | “rhuCD40 mAb induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD40-positive MM cells” PMID 12752100 ↗ May 2003 |
| Modality | Monoclonal antibody | “humanized anti-CD40 monoclonal antibody” PMID 12752100 ↗ May 2003 |
| Route | Intravenous | “Patients received intravenous dacetuzumab” PMID 20133895 ↗ Feb 2010 |
| Target | CD40 | “monoclonal antibody against CD40” PMID 12752100 ↗ May 2003 |